Marina Saresella1, Ivana Marventano2, Federica Piancone2, Francesca La Rosa2, Daniela Galimberti3,4,5, Chiara Fenoglio6,4,5, Elio Scarpini6,4,5, Mario Clerici2,6. 1. IRCCS Fondazione Don Carlo Gnocchi, Laboratory of Molecular Medicine and Biotechnology, Via Capecelatro, 66, 20148, Milan, Italy. marina.saresella@dongnocchi.it. 2. IRCCS Fondazione Don Carlo Gnocchi, Laboratory of Molecular Medicine and Biotechnology, Via Capecelatro, 66, 20148, Milan, Italy. 3. Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy. 4. Centro Dino Ferrari, Milan, Italy. 5. Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy. 6. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Abstract
BACKGROUND: Interleukin-33 is a cytokine endowed with pro- and anti-inflammatory properties that plays a still poorly defined role in the pathogenesis of a number of central nervous system (CNS) conditions including Alzheimer's disease (AD). We analyzed this cytokine and its decoy receptor sST2 in Alzheimer's disease (AD) and mild cognitive impairment (MCI). METHOD: IL-33 and sST2 were analyzed in serum and CSF of AD and MCI patients, comparing the results to those obtained in age-matched healthy controls (HC). Because of the ambiguous role of IL-33 in inflammation, the concentration of both inflammatory (IL-1β and IL-6) and anti-inflammatory (IL-10) cytokines was analyzed as well in serum and cerebrospinal fluid (CSF) of the same individuals. Finally, the effect of IL-33 on in vitro Aβ42-stimulated monocytes of AD, MCI, and HC individuals was examined. RESULTS: As compared to HC, (1) IL-33 was significantly decreased in serum and CSF of AD and MCI, (2) sST2 was increased in serum of AD and MCI but was undetectable in CSF, (3) serum and CSF IL-1β concentration was significantly increased and that of IL-10 was reduced in AD and MCI, whereas no differences were observed in IL-6. In vitro addition of IL-33 to LPS+Aβ 42-stimulated monocytes downregulated IL-1β generation in MCI and HC, but not in AD, and stimulated IL-10 production in HC alone. IL-33 addition also resulted in a significant reduction of NF-kB nuclear translocation in LPS+Aβ42-stimulated monocytes of HC alone. CONCLUSIONS: These data support the hypothesis that IL-33 plays a complex anti-inflammatory role that is lost in AD- and MCI-associated neuroinflammation; results herein also suggest a possible use of IL-33 as a novel therapeutic approach in AD and MCI.
BACKGROUND:Interleukin-33 is a cytokine endowed with pro- and anti-inflammatory properties that plays a still poorly defined role in the pathogenesis of a number of central nervous system (CNS) conditions including Alzheimer's disease (AD). We analyzed this cytokine and its decoy receptor sST2 in Alzheimer's disease (AD) and mild cognitive impairment (MCI). METHOD:IL-33 and sST2 were analyzed in serum and CSF of AD and MCI patients, comparing the results to those obtained in age-matched healthy controls (HC). Because of the ambiguous role of IL-33 in inflammation, the concentration of both inflammatory (IL-1β and IL-6) and anti-inflammatory (IL-10) cytokines was analyzed as well in serum and cerebrospinal fluid (CSF) of the same individuals. Finally, the effect of IL-33 on in vitro Aβ42-stimulated monocytes of AD, MCI, and HC individuals was examined. RESULTS: As compared to HC, (1) IL-33 was significantly decreased in serum and CSF of AD and MCI, (2) sST2 was increased in serum of AD and MCI but was undetectable in CSF, (3) serum and CSF IL-1β concentration was significantly increased and that of IL-10 was reduced in AD and MCI, whereas no differences were observed in IL-6. In vitro addition of IL-33 to LPS+Aβ 42-stimulated monocytes downregulated IL-1β generation in MCI and HC, but not in AD, and stimulated IL-10 production in HC alone. IL-33 addition also resulted in a significant reduction of NF-kB nuclear translocation in LPS+Aβ42-stimulated monocytes of HC alone. CONCLUSIONS: These data support the hypothesis that IL-33 plays a complex anti-inflammatory role that is lost in AD- and MCI-associated neuroinflammation; results herein also suggest a possible use of IL-33 as a novel therapeutic approach in AD and MCI.
Authors: Emma Lefrançais; Stephane Roga; Violette Gautier; Anne Gonzalez-de-Peredo; Bernard Monsarrat; Jean-Philippe Girard; Corinne Cayrol Journal: Proc Natl Acad Sci U S A Date: 2012-01-17 Impact factor: 11.205
Authors: Alissa A Chackerian; Elizabeth R Oldham; Erin E Murphy; Jochen Schmitz; Stefan Pflanz; Robert A Kastelein Journal: J Immunol Date: 2007-08-15 Impact factor: 5.422
Authors: Elizabeth K Brint; Damo Xu; Haiying Liu; Aisling Dunne; Andrew N J McKenzie; Luke A J O'Neill; Foo Y Liew Journal: Nat Immunol Date: 2004-03-07 Impact factor: 25.606
Authors: Amy K Y Fu; Kwok-Wang Hung; Michael Y F Yuen; Xiaopu Zhou; Deejay S Y Mak; Ivy C W Chan; Tom H Cheung; Baorong Zhang; Wing-Yu Fu; Foo Y Liew; Nancy Y Ip Journal: Proc Natl Acad Sci U S A Date: 2016-04-18 Impact factor: 11.205
Authors: Samuel E Marsh; Edsel M Abud; Anita Lakatos; Alborz Karimzadeh; Stephen T Yeung; Hayk Davtyan; Gianna M Fote; Lydia Lau; Jason G Weinger; Thomas E Lane; Matthew A Inlay; Wayne W Poon; Mathew Blurton-Jones Journal: Proc Natl Acad Sci U S A Date: 2016-02-16 Impact factor: 11.205
Authors: Timotheus Y F Halim; Catherine A Steer; Laura Mathä; Matthew J Gold; Itziar Martinez-Gonzalez; Kelly M McNagny; Andrew N J McKenzie; Fumio Takei Journal: Immunity Date: 2014-03-06 Impact factor: 31.745
Authors: Marina Saresella; Francesca La Rosa; Federica Piancone; Martina Zoppis; Ivana Marventano; Elena Calabrese; Veronica Rainone; Raffaello Nemni; Roberta Mancuso; Mario Clerici Journal: Mol Neurodegener Date: 2016-03-03 Impact factor: 14.195
Authors: Alanna G Spiteri; Claire L Wishart; Roger Pamphlett; Giuseppe Locatelli; Nicholas J C King Journal: Acta Neuropathol Date: 2021-12-01 Impact factor: 17.088
Authors: Timofey O Klyucherev; Pawel Olszewski; Alena A Shalimova; Vladimir N Chubarev; Vadim V Tarasov; Misty M Attwood; Stina Syvänen; Helgi B Schiöth Journal: Transl Neurodegener Date: 2022-04-21 Impact factor: 9.883
Authors: Alin Laurentiu Tatu; Anca Arbune; Valentin Chioncel; Elena Niculet; Thomas Nadasdy; Carmen Bobeica; Alina Viorica Iancu; Caterina Dumitru; Valentin Tudor Popa; Nicolas Kluger; Victor Gabriel Clatici; Claudiu Ionut Vasile; Cristian Onisor; Alexandru Nechifor Journal: J Inflamm Res Date: 2022-09-08